Beta-Amyloid forms are deposited in the CNS of patients with Alzheimer’s disease and Down’s syndrome. Biochemical analysis of the amyloid peptides isolated from Alzheimer’s disease brain indicates that Beta-Amyloid (1-42) is the principal species associated with senile plaque amyloids, while Beta-Amyloid (1-40) is more abundant in cerebrovascular amyloid deposits. Both result from the cleavage of Amyloid Precursor Protein (APP) by secretases. The mAb 4G8 reacts to the abnormally processed isoforms, as well as precursor forms.
Host:MouseClone: 4G8Isotype: IgG2bReactivity: Human, MouseImmunogen: This antibody is reactive to residues 17-24 of Beta-Amyloid. The epitope lies within amino acids 18-22 of Beta-Amyloid (VFFAE)Concentration:1 mg/mLFormulation:PBS (no preservatives); The Ab was purified on Protein GApplications:The Ab is effective in immunoblotting (WB), immunohistochemistry (IHC), immunoprecipitation (IP) and ELISA.Working Dilutions:WB: 1/100 - 1/1.000 (predicted MW: APP=~100kDa; beta-Amyloid = 4kDa)
1, Thakker DR et al. (2009) Proc. Natl. Acad. Sci. USA 106(11): 4501-4506.2, Kimura N et al. (2005) Neuropath. Appl. Neurobiol. 31(2): 170-180.3, Klyubin I et al. (2005) Nat. Med. 11(5): 556-561.4, Iijima K et al. Proc. Natl. Acad. Ssi. USA (2004) 101(17): 6623-6628.5, Li M et al. (2004) J. Neurochem. 91: 623-633.